title: Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis.
abstract: A prospective, randomized, controlled clinical trial was performed comparing the antithrombotic efficacy of the low molecular weight heparin LMWH 21-23, (Braun) with an unfractionated heparin in elective general surgical patients over an observation period of 7 postoperative days. A total of 230 patients were admitted: 103 (group I) received low molecular weight heparin and 100 (group II) low-dose unfractionated heparin treatment given subcutaneously. In group I 41 patients (46%) were operated on for malignant disease and in group II 54 patients (54%). Due to the large amount of great abdominal procedures the intra- and perioperative application of hydroxyethyl starch was allowed for volume substitution. None of the patients died due to fatal pulmonary embolism. In group I four patients revealed positive 125I-labeled fibrinogen uptake (3.9%); two patients belonged to the hydroxyethyl starch subgroup. In group II five patients displayed a positive fibrinogen uptake (5%); two belonged to the hydroxyethyl starch subgroup. The results of the hemostaseological investigations (e.g., prothrombin time, activated partial thromboplastin time, thrombin clotting time, fibrinogen, antithrombin III, protein C, plasminogen, alpha 2-antiplasmin, tissue-type plasminogen activator, plasminogen activator inhibitor) revealed no statistically significant differences between groups I and II or their subgroups, although a tendency to prolonged clotting times was observed. The antifactor Xa activity values, however, displayed a statistically significant difference between the two groups (P < 0.05). The antifactor Xa activity measured up to 0.16 U/ml for the low molecular weight heparin (group I) and 0.05 U/ml for the unfractionated heparin (group II) in the postoperative period.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Abteilung Allgemeine Chirurgie, Klinikum, Universität Ulm, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Limmer
authors.forename: D
authors.initials: D
authors.lastname: Ellbrück
authors.forename: H
authors.initials: H
authors.lastname: Müller
authors.forename: E
authors.initials: E
authors.lastname: Eisele
authors.forename: J
authors.initials: J
authors.lastname: Rist
authors.forename: F
authors.initials: F
authors.lastname: Schütze
authors.forename: H
authors.initials: H
authors.lastname: Beger
authors.forename: H
authors.initials: H
authors.lastname: Heimpel
authors.forename: E
authors.initials: E
authors.lastname: Seifried
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis / Q000517:prevention & control*; D011446:Prospective Studies; D013924:Thrombophlebitis / Q000175:diagnosis / Q000517:prevention & control*
chemical_list: D006495:Heparin, Low-Molecular-Weight; D006493:Heparin